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Abstract
Early diagnosis of Duchenne muscular dystrophy (DMD) is widely advocated to initiate proactive interventions and genetic counselling. Genetic
testing now allows the diagnosis of DMD even prior to the onset of symptoms. However, little is known about care practices and their impact on young
DMD boys and families after receiving an early diagnosis. We analysed 64 young boys (Japan, 19; the United Kingdom, 10; Germany, 18; Hungary, 6;
Poland, 5; and the Czech Republic, 6) aged <5 years and diagnosed at ≤2 years old among the participants of the cross-sectional study about care practice
in DMD.A combination of elevated serum creatine kinase and genetic testing usually led to the diagnosis (n = 31, 48%); 41 boys visited neuromuscular
clinics more than once a year. Early diagnosis did not generally result in higher satisfaction among DMD families, and country-specific differences were
observed. Psychosocial support following early diagnosis was perceived as insufficient in most countries, and deficits in access and uptake of genetic
counselling resulted in lower satisfaction in the Japanese cohort. In conclusion, seamless and comprehensive support for DMD families following early
diagnosis at presymptomatic stages should be taken into consideration if early genetic testing or newborn screening is made available more widely.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X linked condition
characterized by progressive muscle weakness and wasting due
to absence of the protein dystrophin in the muscles [1]. DMD
is the most common muscular dystrophy in children and affects
approximately one in every 4000 newborn males [2]. Affected
boys typically present with motor development disorder or
speech delay and muscle weakness in early childhood [3].
Since the introduction of steroid treatment, nocturnal ventilation,
Present/permanent addresses: Fumi Takeuchi: Institute of Genetic
Medicine, International Centre for Life, Newcastle University, Newcastle upon
Tyne, UK and The John Walton Muscular Dystrophy Research Centre, MRC
Centre for Neuromuscular Diseases, Newcastle University, Central Parkway,
Newcastle upon Tyne, NE1 3BZ, UK; Takeo Kubota: Faculty of Child Studies,
Seitoku University, Iwase 550, Matsudo, Chiba, 271-8555, Japan.
* Corresponding author. Department of Clinical Research Support,
Translational Medical Center, National Center of Neurology and Psychiatry,
4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8551, Japan.
E-mail address: hnakamura@ncnp.go.jp (H. Nakamura).
http://dx.doi.org/10.1016/j.nmd.2017.06.557
0960-8966/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Available online at www.sciencedirect.com
Neuromuscular Disorders 27 (2017) 894–904
www.elsevier.com/locate/nmd
ScienceDirect
and cardiac support in the last 10–15 years, clinical outcomes
and life expectancy have improved significantly [4,5]. Currently,
a boy with DMD managed according to these Care Standards
has a good chance of living well into his 30s [6]. In recent
years, new and promising therapeutic approaches, such as exon
skipping therapy, have been developed, trying to restore dystrophin
expression in the muscle [7]. Some of these are currently in
the clinical trial phase.
On the other hand, there has been little improvement in
lowering the age at diagnosis of DMD, still averaging between
4.5 and 5.0 years despite developments in genetic testing and
increasing awareness of DMD [6,8–13], although few related
studies have been reported from Japan. Diagnostic delay is
increasingly recognized to have a negative impact on clinical
outcomes [6]. To avoid diagnostic delay, earlier creatine kinase
(CK) testing in primary care is emphasized, because of its
cost-effectiveness, ready availability, and high sensitivity and
specificity [6,8]. In addition, newborn screening for DMD has
been piloted in a number of centers in the world, especially in
western countries [14]; however, screening newborns for
conditions for which limited treatment options exist is
controversial due to concerns about the impact a positive
screening result may have on the parent–child relationship [15].
Early diagnosis is believed to provide patients and families
several benefits: (1) it allows them to make informed decisions
regarding future planning; (2) it ensures early access to
standards of care (steroid treatment, physiotherapy, and
appropriate screening for cardiomyopathy); and (3) it allows
participation in research and potentially allows access to
clinical trials with new investigational drugs [6]. However,
there has been few research which reported care practice in
young boys and their families with early diagnosis, especially
before 5 years of age when steroid treatment (one of the main
interventions in early disease stage) is typically initiated [4,16].
This study explores the real-life experience of DMD families
with care and support including help for coping with diagnosis,
following early diagnosis, and highlights some differences
between Japan and European countries based on differences in
culture and healthcare systems.
2. Participants and methods
2.1. Study population
The CARE-NMD project has conducted a cross-sectional,
multi-center study surveying care practices and quality of life in
patients with DMD in 7 European countries – Bulgaria (BG),
the Czech Republic (CZ), Denmark (DK), Germany (GE),
Hungary (HU), Poland (PL), and the United Kingdom (UK)
since 2011, followed by Japan (JP) since 2012 [17,18]. The 7
European countries were selected because of well-established
DMD patient registries and to broadly represent different
healthcare systems and public expenditure on health. The health
expenditure to gross domestic product ratio is below the EU
average in all Eastern European and above the average in all
Western European countries participating in this project. Out of
the valid responses, we extracted participants diagnosed early
(at ≤2 years old) and currently aged <5 years old.
2.2. Survey procedure
The study was approved by the ethics committee at the
University Medical Center Freiburg, and as a condition of
distribution via national DMD patient registries, was also
approved by the TREAT-NMD Global Database Oversight
Committee [17,18]. The approval for conducting this survey in
Japan was granted by the National Center of Neurology and
Psychiatry (NCNP) Ethics Committee. Survey participation
was voluntary, and we regarded a reply to the questionnaire as
agreement to participate. The survey consisted of 42 questions
that captured socio-demographic variables, as well as
information about daily life, functional abilities, disease
progression, and medical and social care received. The
questionnaire translated into the local language by project
partners in each country was distributed in each country on
behalf of the project via national DMD patient registries, which
form part of the TREAT-NMD Global DMD Registries [17,18].
Data from Europe were collected between September 2011 and
April 2012, and those from Japan between June 2012 and
March 2013. Mail replies were inputted into the SurveyMonkey
questionnaire (www.surveymonkey.com).
2.3. Measurements
For this study, we extracted the questionnaire items as
follows: method of diagnosis confirmation, help given for
coping with the diagnosis, neuromuscular clinic and
physiotherapy attendance, information provided (genetic
counselling, disease course, special learning needs, patient
organizations), treatment (home stretch advice, speech therapy,
psychological support), attitude towards the community,
involvement with patient advocacy groups, and overall
satisfaction.
2.4. Statistical analysis
We wish to compare the families’ satisfaction with the care
received in Japan and European countries. While there are
differences even within Europe, cultural background and
healthcare in Japan are believed to have significant differences
in comparison to all European countries, eg the much higher
life expectancy of patients with DMD or ALS in Japan as
compared to Europe. We statistically analysed questionnaire
responses about information given, treatment (except for
speech therapy) received, and overall satisfaction using chi-
square tests. In terms of questions about information and
treatment, we compared “Yes, sufficiently” (“satisfaction
group”) and the others (“dissatisfaction group”). In terms of
overall satisfaction, the sum of “Very satisfied” and “Rather
satisfied” (satisfaction group) was compared with the others
(dissatisfaction group). For the conservativeness of the
statistical-test, we allocated “No response” in Japanese cohorts
to “satisfaction group” and that in European cohorts to
“dissatisfaction group”. We considered p-values <0.05 to be
significant. Data analysis was conducted by SAS® version 9.4
(SAS Institute Inc., Cary, NC, USA) or Microsoft Excel 2010.
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3. Results
3.1. Demographics
“How old were you/was your son, when DMD was
confirmed either genetically or by muscle biopsy, NOT only
based on symptoms or elevated CK in blood?”
Out of 2401 questionnaires sent out, 1465 replies were
collected (61% response rate). The response rate of each
country is shown in Table 1. A total of 110 boys (7.6%) aged <5
years were identified, of which 64 (4.8%) were diagnosed at ≤2
years: these were eligible for our study. The 64 study subjects
consisted of 19 in Japan, 10 in United Kingdom, 18 in
Germany, 6 in Hungary, 5 in Poland, and 6 in Czech Republic.
No boys in Bulgaria or Denmark met our inclusion criteria
(Fig. 1). The median age at diagnosis, current age, and time
since diagnosis in the 64 boys was 1.0, 3.25, and 2.0 years,
respectively (Table 2).
3.2. Diagnosis of DMD
3.2.1. Confirmation of the diagnosis
“How was the diagnosis of DMD established in your case?
You may mark more than one answer.”
Fig. 2a describes the DMD diagnostic approach according to
the self-reported data from patients and their families. A
combination of elevated serum CK and genetic testing of blood
samples led to the diagnosis in 31 (48%) cases. Other early
diagnostic clues included signs at physical assessment in 13
cases (20%), and positive family history in 3 (5%, 1 Japan and
2 Czech Republic). A muscle biopsy was performed in 12 boys
(19%). Genetic testing was performed in the all participants and
DMD confirmed as a mandatory inclusion criterion in the
registry.
3.2.2. Help for coping with diagnosis offered by doctor at
diagnosis (Fig. 2b)
“What kind of help for coping with the diagnosis was offered
to you by your doctor at the time of diagnosis?You may mark
more than one answer.”
Table 1
Participants of the CARE-NMD survey.
Country JP UK GE HU PL CZ BG DK Total
Population (×106)* 12.7 6.2 8.3 1.0 3.8 1.1 0.7 0.6 34.4
Sent out, n 724 421 545 70 246 191 73 131 2401
Total replies received, n (%) 394 (54) 226 (54) 420 (77) 57 (81) 142 (58) 89 (53) 40 (55) 88 (67) 1465 (61)
Replies re: boys aged <5 yo, n (%) 30 (7.6) 13 (5.8) 34 (8.1) 9 (15.8) 10 (7.0) 10 (11.2) 1 (2.5) 3 (3.4) 110 (7.6)
Replies re: boys aged <5 and
diagnosed ≤2 yo, n (%)
19 (4.8) 10 (4.4) 18 (4.3) 6 (10.5) 5 (3.5) 6 (6.7) 0 (0) 0 (0) 64 (4.4)
JP, Japan; UK, the United Kingdom; GE, Germany; HU, Hungary; PL, Poland; CZ, the Czech Republic; BG, Bulgaria; DK, Denmark; re,regarding; yo, year old.
* United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision, DVD Edition.
CARE-NMD survey questionnaires sent out to 2401 patients
(JP: 724, UK: 421, GE: 545, HU: 70, PL: 246, CZ: 191, BG: 73, DK: 131)
Study subjects: 64
(JP: 19, UK: 10, GE: 18, HU: 6, PL: 5, CZ: 6, BG: 0, DK: 0)
Current age < 5 years 
936
1355
110 
Diagnosed at 
≤2 years of age 
46
1465 valid replies
Fig. 1. Study flowchart. CARE-NMD questionnaires were sent out to 2401
patients in DMD registries in Japan and 7 European countries. Out of 1465
valid replies, 110 affected boys had a current age of <5 years, and 64 of those
were diagnosed at ≤2 years of age. JP, Japan; UK, the United Kingdom; GE,
Germany; HU, Hungary; PL, Poland; CZ, the Czech Republic; BG, Bulgaria;
DK, Denmark.
Table 2
Demographics.
JP UK GE HU PL CZ Total
(n = 19) (n = 10) (n = 18) (n = 6) (n = 5) (n = 6) (n = 64)
Age at diagnosis: (years. months) Median, range 1.3 0.9 0.11 1.0 1.0 0.11 1.0
0.7–2.0 0.1–2.0 0.3–1.8 0.6–1.6 0.5–2.0 0.3–2.0 0.1–2.0
Current age: (years. months) Median, range 3.6 3.5 2.8 2.7 3.2 3.6 3.3
1.5–5.0 2.5–4.8 0.10–4.6 1.10–4.8 2.4–4.5 1.6–4.4 0.10–5.0
Time since diagnosis: (years. months) Median, range 2.1 2.3 1.11 1.6 2.0 2.2 2.0
0.7–4.5 0.9–4.2 0.5–3.9 1.2–3.7 1.2–3.5 0.9–3.6 0.5–4.5
JP, Japan; UK, the United Kingdom; GE, Germany; HU, Hungary; PL, Poland; CZ, the Czech Republic.
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At the time of DMD diagnosis, 38 (59%) parents/caregivers
reported being offered “some help”, 12 were offered “not
appropriate” help, 7 responded that help was “not needed”,
and 3 responses were “unknown”. In the Japanese cohort, 9
parents/caregivers (47%) answered with “offered some help”,
which was lower than that for the 6 European cohorts (United
Kingdom: 10, 70%; Germany: 12, 67%; Hungary: 3, 50%;
Poland: 3, 60%; Czech Republic: 4, 67%). Then, “what kinds
of help did your doctor offer?” was asked to those who had
been offered some help (more than one answer was allowed).
Twenty-five parents/caregivers reported being given “Brochures/
Website“ (Japan: 4, United Kingdom: 6, Germany: 9, Hungary:
1, Poland: 1, and Czech Republic: 4), 21 reported being allowed
“Sufficient time to talk to doctor or a second appointment with
the doctor” (Japan: 3, United Kingdom: 4, Germany: 9, Hungary:
1, Poland: 0, and Czech Republic: 4), 11 reported “Referral to
support group” (Japan: 0, United Kingdom: 0, Germany: 9,
Hungary: 1, Poland: 1, and Czech Republic: 0), 11 reported
“contact with social worker/care coordinator” (Japan: 0, United
Kingdom: 3, Germany: 8, Hungary: 0, Poland: 0, and Czech
Republic: 0), 10 reported “Taking part in courses for families
with DMD” (Japan: 4, United Kingdom: 1, Germany: 1, Hungary:
0, Poland: 0, and Czech Republic: 4), and 9 reported “Contact
with psychologist” (Japan: 2, United Kingdom: 2, Germany: 2,
Hungary: 0, Poland: 1, and Czech Republic: 2). It seemed that
the parents/caregivers of more boys in United Kingdom, Germany,
and Czech Republic received help for coping with diagnosis
than in Japan, Hungary, and Poland.
3.3. Attendance at neuromuscular clinics
“Do you/does your son attend a clinic where the medical
staff specialize in neuromuscular disorders? If yes, how
often?”
The frequency of attendance at a neuromuscular (NMD)
clinic which was recognized as a specialized clinic by the
parents/caregivers is shown in Fig. 3a. Half of the boys (n = 32)
attended at least once every 6 months, 19 (30%) at least once a
Fig. 2. Diagnosis. At confirmation of the diagnosis: (a) The means of diagnosis and (b) the help offered by doctor for coping with the diagnosis, by country. All of
CARE-NMD study participants were confirmed DMD by genetic testing and provided their genetic testing report to DMD registry in each country.
Fig. 3. Attendance. Attendance at (a) neuromuscular clinic and (b) physiotherapy, by country.
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year, 9 (1%) less than once a year, and 4 (6%) did not attend at
all. In the Japanese cohort, 17 (89%) boys attended more than
once annually, which was a slightly higher percentage than the
6 European countries: United Kingdom (n = 7, 70%), Germany
(n = 14, 78%), Hungary (n = 5, 83%), Poland (n = 3, 60%), and
Czech Republic (n = 5, 83%).
3.4. Information about DMD which a medical professional
ever talked (Fig. 4)
“Has a medical professional ever talked to you/your son
about. . ..”
3.4.1. Genetic counselling
In terms of satisfaction among the parents/caregivers of the
64 boys with the information received on genetic counselling,
45 (70%) answered “sufficiently”, 8 (13%) “Yes, but not
enough”, 7 (11%) “No, not at all”, 2 (3%) “I don’t know”, and
2 (3%) didn’t answer. In the Japanese cohort, 9 (47%) answered
“sufficiently”, 4 (21%) “Yes, but not enough”, 4 (21%) “No, not
at all”, and 2 (11%) “I don’t know”. The Japanese cohort’s
satisfaction with information on genetic counselling was
significantly lower than that of the European cohorts
(p = 0.009).
3.4.2. The disease course and main problems that may arise
About the satisfaction with information on DMD overall, 41
(64%) of parents/caregivers replied “sufficiently”, 17 (27%)
“Yes, but not enough”, 4 (6%) “No, not at all”, 1 (2%) “I don’t
know” and 1 didn’t answer. There was no significant difference
between the Japanese cohort and European cohorts (p = 0.504).
3.4.3. Adequate schooling or special learning needs of some
children with DMD
Regarding satisfaction with information given about
education, the parents/caregivers of only 12 boys (19%)
answered “Yes, sufficiently”, 13 (20%) “Yes, but not enough”,
29 (45%) “No, not at all”, and 7 (11%) “I don’t remember”.
There was no significant difference between the Japanese
cohort and European cohorts (p = 0.759).
3.4.4. Patient organizations
About the satisfaction with information on patient
organizations, the parents/caregivers of 27 boys (42%) reported
Fig. 4. Information. Provision of information by clinicians about (a) genetic counselling, (b) main problem of DMD, (c) cognition, and (d) patient organization, by
country.
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“Yes, sufficiently”, 13 (20%) “Yes, but not enough”, 20 (31%)
“No, not at all”, and 2 “I don’t remember”. No significant
difference was shown between the Japanese cohort and
European cohorts (p = 0.264).
3.5. Treatment of DMD (Fig. 3b, Fig. 5)
3.5.1. Professional physical training, stretching or exercises
and instruction of home stretch
“Does your son currently receive physical training,
stretching, or other physical exercises from a qualified
professional?”
“Have you/has your son ever been instructed in doing
stretching at home?”
As shown in Fig. 3b, 13 boys (20%) received
physiotherapy ≥60 minutes weekly, 15 (23%) <60 minutes
weekly, 12 (19%) had previously received physiotherapy, while
23 (36%) had never received it. In the Japanese cohort, no one
received physiotherapy for more than 60 minutes weekly, and 4
(21%) boys received less than 60 minutes weekly. The
percentage of boys receiving regular physiotherapy in Japan
was lower than in the 6 European countries. The result of United
Kingdom was similar to that of Japan in that 5 (50%) boys in
United Kingdom had never received PT. On the other hand, all
Hungarian boys received regular PT.
About the satisfaction with home stretch advice, the 23
(36%) parents/caregivers answered “Yes, sufficiently”, 17
(27%) “Yes, but not enough”, 17 (27%) “No, not at all”, 5 (8%)
“I don’t need it”, and 1 (2%) “I don’t remember”. There was no
significant difference between the Japanese cohort and
European cohorts (p = 0.104).
3.5.2. Speech therapy
“Does your son currently receive speech therapy?”
In terms of speech therapy, 4 (6%) boys (1 PL, 2 DE, and 1
UK) received “60 minutes or more weekly”, 5 (8%) boys (1
Czech Republic, 1 Poland, 1 Germany, 1 United Kingdom, and
1 Japan) “less than 60 minutes weekly”, 4 (6%) boys (2
Germany and 2 United Kingdom) “had received it before” and
46 (72%) had “never received” speech therapy.
Fig. 5. Treatment. Treatment for DMD in terms of (a) home stretch advice, (b) speech therapy, (c) psychological support by country.
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3.5.3. Psychological support for coping with the diagnosis
“Have you/has your son received psychological support for
coping with the diagnosis or in managing daily life?”
In terms of satisfaction with the psychological support
provided, the parents/caregivers of 6 (9%) boys replied “Yes,
sufficiently”, 8 (13%) “Yes, but not enough”, 36 (56%) “No, not
at all”, and 11 (17%) “I don’t need it”.
There was no difference between the Japanese cohort and
European cohorts regarding satisfaction with psychological
support (p = 0.605) received.
3.6. Involvement with community, patient advocacy group
(Fig. 6)
3.6.1. Attitude towards community
“Do you/does your son believe that you are/your son is
viewed on equal terms by other citizens in your local
community?”
The parents/caregivers of 32 (50%) boys believed that their
affected boys were viewed on equal terms by other citizens in
the local community “Yes, always”, 21 (33%) “Most of time”, 3
(5%) “Sometimes”, 2 (3%) “Seldom”, and 2 (3%) “Never”. In
the Japanese cohort, 7 (37%) answered “Yes, always” or “Most
of time”, 1 (5%) “Sometimes”, 2 (11%) “Seldom” and 1 (5%)
“Never”.
3.6.2. Members of patient advocacy groups
“Is anyone in the family a member of a patient advocacy
group for Duchenne or neuromuscular disease in general?”
Overall, 23 (36%) of the boys’ family members were
involved with a patient advocacy group for DMD or NMD.
Czech families were involved with a patient advocacy group
most frequently (n = 4, 67%), while no Polish families were
involved (Japan; 6, 32%, United Kingdom; 3, 30%, Germany;
9, 50%, Hungary; 1, 17%, Poland; 0, 0%, Czech Republic; 4,
67%). This distribution was similar to the provision of
information about patient organizations, as shown in Fig. 4d.
3.7. Satisfaction with overall treatment
“How satisfied are you with your overall medical
treatment?”
In terms of satisfaction with overall treatment (Table 3), the
parents/caregivers of 11 (17%) answered “Very satisfied”, 28
(44%) “Rather satisfied”, 18 (28%) “Rather unsatisfied”, and 3
(5%) “Not satisfied at all”. In the Japanese cohort, no responses
of “very satisfied”, 6 (32%) “Rather satisfied”, 9 (47%) “Rather
Fig. 6. Involvement. (a) Attitude towards community, and (b) members of patient advocacy groups, by country.
Table 3
Satisfaction with overall treatment.
Country, and response, n (%) JP UK GE HU PL CZ Total
19 (100) 10 (100) 18 (100) 6 (100) 5 (100) 6 (100) 64 (100)
Very satisfied 0 (0) 4 (40) 6 (33) 0 (0) 0 (0) 1 (17) 11 (17)
Rather satisfied 6 (32) 3 (33) 10 (56) 2 (33) 3 (60) 4 (67) 28 (44)
Rather not satisfied 9 (47) 2 (20) 2 (11) 3 (50) 1 (20) 1 (17) 18 (28)
Not satisfied at all 1 (5) 0 (0) 0 (0) 1 (17) 1 (20) 0 (0) 3 (5)
No response 3 (16) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 4 (6)
JP, Japan; UK, the United Kingdom; GE, Germany; HU, Hungary; PL, Poland; CZ, the Czech Republic.
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unsatisfied” were given, while 1 (5%) respondent answered
“Not satisfied at all”. Satisfaction in the Japanese cohort was
significantly lower than that in European cohorts (p = 0.046).
4. Discussion
This was an observational cross-sectional study focusing on
care practices for young boys diagnosed DMD at ≤2 years and
their families. Our study revealed diagnostic method, some
discrepancies between care practices and care recommendations,
and some differences of parents’ satisfaction with care practice
between Japanese and European cohorts.
4.1. Study findings
4.1.1. Diagnosis
In the Japanese cohort, early diagnosis was most frequently
established by means of the combination of elevated serum CK
and genetic testing, consistent with the European countries. In
three quarters of the boys, family history or physical assessment
was not reported as a diagnostic clue, which may imply that
their muscle condition was pre-symptomatic, and the traditional
diagnostic pathway (for example, noticing delay in attainment
of independent walking) was not used for their early diagnosis.
Currently, genetic testing is performed for diagnosis in most
cases, showing a specific mutation in DMD gene. All of CARE-
NMD study participants provided their genetic testing result to
register the DMD registry in each country. Muscle biopsy is
now only recommended when initial genetic testing is
inconclusive or the patient has an unusual phenotype [6]. In our
cohort, only 19% of boys had a muscle biopsy performed, while
49.3% of 1062 patients with DMD (mean age: 13.0 years old)
in the total CARE-NMD survey cohorts [18] reported diagnosis
by muscle biopsy, which supports the suggestion that genetic
testing development ensures easier, faster and less invasive
diagnosis of DMD in young cohorts.
4.1.2. Discrepancy between real world care practice and
DMD guideline recommendations
In this study, most boys (60–89% of each country) attended
NMD clinics at least once a year. This might suggest that early
diagnosis ensures early access to NMD clinics. However, some
discrepancy between care practice and guideline recommendations
were also observed [4]. First, wide variation in physiotherapy
accessibility and/or home stretch advice was observed in the 6
countries. The international guideline recommends preventive
measures to maintain muscle extensibility and/or minimize
contractures between the pre-symptomatic and early ambulatory
stage [4]. However, in our cohort, all Hungarian boys accessed
regular physiotherapy, while less accessibility was shown in
the boys of Japan, Czech Republic, and the United Kingdom.
The related study documented very low rates of access to
professional physiotherapy in the United Kingdom generally
with low rate in the paediatric cohort [17]. Second, psychological
support, information on cognitive delay, and speech therapy
seemed to be insufficient overall, despite the fact that family
support, early assessment and/or intervention for development,
learning, and behaviour is recommended in the pre-symptomatic
stage [4].
In the current study, care practice varied by country and/or
individual. The heterogeneities and poor agreement with DMD
clinical guidelines were also shown in the previous reports from
Western countries examining different aspects of self-reported
real-world DMD care in various settings by country [17–19].
The first compared care practice in 201 adult (≥18 years) DMD
patients extracted from CARE-NMD survey participants in 7
European countries (United Kingdom, Germany, Hungary,
Poland, Czech Republic, Bulgaria, and Denmark) [17,18]. The
second analysed the experience of medical management of 770
DMD patients (aged ≥5 years) in Germany, Italy, the United
Kingdom, and the United States in comparison to the clinical
guidelines [19]. Neither international studies related DMD
focused on paediatric cohorts aged <5.0 years with early
diagnosis, or socio-epidemic comparative studies between
Asian and Western countries had been reported. Although this
study sample was very small, the observed heterogeneities
support the previous findings [17–19].
As noted in previous studies, there are several potential
reasons for differences between care guidelines and
implementation. First, we noted differences in the delivery of
and access to care in general, and the availability of specialized
NMD clinics [17–19]. Second, national healthcare systems differ;
government funded programs versus private insurance schemes
and the degrees of cost sharing for services might affect the
provision of healthcare, as well as the ability and willingness
to utilize healthcare services. Third, at the time this study was
conducted, clinicians may not yet have been aware of the
international guidelines. This survey was conducted in between
2011 and 2012, while the international guidelines were published
in 2010 [4,5], followed by Japanese care guidelines in 2014
[20]. Finally, there may be factors specific to those boys in the
early ambulatory stage of the condition, such as that they
attend NMD clinics less frequently than those in later stages.
Alternatively, it is also possible that they attend a non NMD
clinic more often. Later on, at least 6-monthly assessment is
recommended to define disease phase and determine need for
intervention and management with steroid therapy [4,18].
4.1.3. Care practice in Japan
In this study, characteristic care practices in Japan were
observed in comparison to the 5 European countries. In spite
of a higher percentage of regular NMD clinic attendance in
Japanese cohorts, significantly lower satisfaction with information
on genetic counselling and overall care and treatment was
observed.
Generally, the Japanese healthcare system allows easy access
to medical care and treatment from primary to tertiary. Moreover,
in some hospitals, CK is performed as a routine blood test,
which might be different from healthcare systems of the other
countries [6,8–13] and which may result in an incidental elevated
CK finding. Moreover, health insurance has covered MLPA
genetic testing to diagnose on DMD/BMD since 2006 [21],
with genetic counselling since 2012 [20]. The additional genetic
testing with whole-exon sequence for small DMD gene mutation
is available from the research institute of NCNP free of charge
to patients who are willing to participate in the Japanese national
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registry of muscular dystrophy (Remudy) [22,23]. Interestingly,
Japanese cohort’s satisfaction with information on genetic
counselling and overall treatment was significantly lower than
that of European cohorts, in spite of the accessibilities of
diagnostic testing from CK to genetic testing and higher regular
attendance of neuromuscular clinic. In addition, satisfaction
with information on genetic counselling was lower than that
with information provision on the main problems associated
with DMD, which was not observed in European cohorts. In a
previous Japanese survey of 66 families affected by muscular
dystrophy, information on the nature of the disease and prognosis
was provided more often than genetic information (such as
relationship between dystrophy and genetic abnormality, and
the availability of carrier tests) by attendant physicians [24].
Interestingly, the Japanese population, not limited to DMD
families, is generally reporting lower satisfaction according to
the OECD Better Life Index [25] and World Happiness Report
[26]. In addition, we hypothesize that the lower satisfaction of
DMD families may be multifactorial and includes the availability
or access to genetic counselling, provision of help for coping
with diagnosis, and cultural attitudes and belief towards genetic
diseases which are often hidden or not talked about. For older,
more disabled patients with DMD, Japan provides 27 hospitals
with specialized wards, where experienced multidisciplinary
teams provide care [23]. In contrast genetic counselling, which
is more important for younger patients and families, has not
been fully established and costs are not fully covered by the
public requiring direct payment by the families. However, as
genetic testing and genetic research become more popular in
Japan, the establishment of a national genetic counselling system
was required [27]. In fact, specific genetic counselling departments
have recently been set up, and more than 100 hospitals have
opened genetic counselling clinics as of November 2014 [28].
Second, genetic issues have been treated as a taboo topic by
clinicians traditionally, although the situation has improved.
Several factors such as culture, society, history, and genetic
literacy should be considered that shape the opinion of the
wider public towards genetic issues [29]. Indeed, the discrimination
against minorities, including people with hereditary diseases
and disabilities globally, although diminishing, still exists. In
Japanese custom, the “family” has traditionally been more
valued than the “individual”. Consequently, having a hereditary
disease used to be recognized as “family’s shame” and was
kept in secret in some families [30]. Moreover, it has been
discussed that insufficiency of genetic education in school
interfered with promoting genetic literacy [29,31,32]. In the
previous surveys, lower literacy and interest in science and
technology was shown for the Japanese population in comparison
to the United States and Europe [33,34]. To improve genetic
education, efforts have been made in schools and in the general
public [31]. Finally, the availability of help for coping with
diagnosis has been correlated to the parents’ satisfaction.
According to Green [35], the only independent predictors of
parents’ satisfaction with diagnosis of DMD were obtaining
the information that they wanted and feeling that they had
understood and remembered it. In this study, fewer than half of
the Japanese cohort reported being “offered some help” at the
time of diagnosis, which was not significantly different between
Japanese and European cohorts. Moreover, support tools for
coping with diagnosis offered to Japanese families seemed to
be limited in comparison to those of the United Kingdom,
German, and Czech families. Among 377 Japanese participants
in CARE-NMD survey, the satisfaction with overall treatment
is slightly better in the patients diagnosed at 2–5 years old in
comparison to the patients diagnosed at 0–1 year old.
(Supplementary Table S1).
The attitude towards the community seemed to be positive
among all the cohorts, which might be associated with the early
disease stage we analysed, because the consequences of DMD
(for example, physical limitations) can result in social isolation,
withdrawal, and less access to social activities [4]. The families’
participation in patient advocacy group showed inconsistency
by country, in a distribution similar to the provision of
information on patient organizations by clinicians. Even if
patients’ families were offered the information, participation in
patient communities would depend on individual perception. For
some families with young boys in the pre-symptomatic stage of
DMD, participation in patient communities may be challenging.
4.2. Optimization of early diagnosis
To optimize early diagnosis, it is important to make DMD
care guidelines accessible to healthcare staff, patients, and their
caregivers. It also requires worldwide efforts to pre-identify
multidisciplinary care centres with committed neuromuscular
leaders and nurse specialists, genetic counselling resources,
and access to other specialty care so that early diagnosis can
offer benefits to the boys and their families. One example of
this is provided by the cystic fibrosis care system, where consistent
interventions are used across care centers, and clinical outcomes
arise from a series of ongoing assessments with results recorded
in a central patient registry and reported regularly to the public.
Additionally, ongoing efforts have been invested to link paediatric
and adult care clinics, providing a seamless transition from
paediatricians to internists with multidisciplinary teams [36].
Our findings suggest that for families with young boys diagnosed
with DMD, obtaining helpful information appears to be
challenging. It was notable that “brochures/websites” were the
most frequently used form of assistance in coping with the
diagnosis. As this suggested, information packages for families,
including language-specific web resources providing information
on care guidelines, up-to-date treatment options, supportive
technologies, and opportunities for clinical trials are essential
for patients and families to cope with diagnosis, have a raised
awareness and become empowered. In fact, up-to-date, useful
information on DMD has been currently accessible on various
websites, which are more available in English than in the other
languages including Japanese. As the CARE-NMD website
(http://www.care-nmd.eu) and DMD Care Guidelines App
(http://www.treat-nmd.eu/care/dmd/family-guide/smartphone)
provides, it is important to make essential information for
DMD available worldwide. Moreover, it is important to facilitate
additional innovative services which meet the unique needs of
the DMD population, for example, information and/or
communication by using social media [37].
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4.3. Future research
The importance of natural history data of infant and young
boys with DMD is widely recognized [3,38–40]. It is hoped that
the effect of early interventions (medication with steroids
[36,41]/new drugs, physiotherapy and speech therapy) on
physical outcomes, social interaction [42], quality of life, and
satisfaction with care will be revealed in the near future.
Therefore, it is important to carry out a preliminary study in
young boys with early diagnosis. Consequently, some of these
strategies may have the potential to decrease the burden of the
disease and improve the overall quality of life and daily
functioning for DMD patients [43].
4.4. Study limitation
We recognize some limitations due to the cross-sectional
study design which used existing survey data regarding care
and treatment, and may be subject to recall bias. The sample
sizes from each country are too small to give accurate information
about treatment options, and therefore the benefits and harms
of early diagnosis could not be assessed. In addition, our small
sample might have some possible sources of selection bias.
Caregivers that are particularly involved in the care for their
child may be more interested and motivated to be involved in
our study, resulting in an overestimation of the overall care
experience. On the other hand, patient-caregiver pairs that were
particularly dissatisfied with care could possibly also have been
more motivated. In spite of these limitations, we believe that
overall our study is likely to be a representative snapshot of the
experience of early diagnosis of DMD in the 6 countries surveyed.
5. Conclusion
This study described current care practices for young boys
diagnosed early with DMD. This has not been fully described
in previous studies. In the long term, whether or not early
diagnosis is beneficial for our cohorts in real world remains
unknown. However, we provide some evidence that there are
still a lot of issues to be addressed to optimize the early diagnosis
of DMD from the perspective of the parents. International
research and clinical trials in DMD have been well developed,
and diagnostic testing development will increase the number
of young boys diagnosed early, while we also need to keep in
mind their heterogenic background. Seamless support and care
for DMD families with early diagnosis at presymptomatic stages
may be required, as more patients will be diagnosed early in
the future with the ease of genetic testing and potential newborn
screening programs on the horizon.
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